Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Primary mode of action: FDA lengthens the deadline for receiving stakeholder comments on the agency's proposed rule defining "mode of action" and "primary mode of action" to Aug. 20, following AdvaMed request for a 60-day extension, according to a June 24 Federal Register notice. FDA issued the proposed rule clarifying the mechanism for assigning jurisdiction of combination products May 7 (1"The Gray Sheet" May 10, 2004, p. 12). Comments initially were due July 6...
You may also be interested in...
FDA Solicits Stakeholder Comment On Pediatric Device Needs
FDA plans to issue a Federal Register notice shortly to collect information on obstacles to bringing pediatric devices to the U.S. market
Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register
FDA Proposed Rule Trims Preamendments Reclass List By Three
PMAs would be required for indwelling blood oxyhemoglobin concentration analyzers, cardiopulmonary bypass pulsatile flow generators and ocular plethysmographs, according to a 1Nov. 18 FDA proposed rule